David Brunel is an entrepreneur with over 35 years of experience building and growing successful companies. Mr. Brunel was a co-founder and CEO of UniData, Inc., an enterprise software company focusing on database and data-driven business intelligence tools. UniData merged with Ardent Software, Inc. in 1997, where Brunel served as President/COO until it was sold to Informix in 1999. Following his tenure at Ardent, Mr. Brunel co-founded and served as President of SomaLogic, Inc., a company focused on creating protein capture arrays for sensitive, high-throughput, quantitative diagnostics. He also was a founding investor in Xyleme, Inc. and later as CEO and Chairman. Xyleme was sold to Bow River Capital in 2021. In 2006, he co-founded Biodesix, Inc., a molecular diagnostic company using genomics and proteomics to create and deliver diagnostics tools to aid in the detection and treatment of lung cancer and other lung disease. Brunel served as CEO from its founding until January 2020. Biodesix is currently public under the symbol BDSX. He also serves on the board of Kromatid, Inc, a leader in the discovery and detection of complex genetic changes providing unique solutions to biotech companies involved in gene editing and cell engineering. He also serves as the Board Chairman of Amidebio, a biotech company pursuing therapeutic solutions in metabolic disease and he currently serves as the Executive Chairman of Anark Corporation, an emerging leader in providing digital collaboration solutions for engineering, auto, electronics, defense and aerospace companies.